Eylea Safety Versus Ease Of Reimbursement Frames Advisory Cmte. Discussion Of Dosing
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA panel unanimously backs the wet age-related macular degeneration therapy with support for a bi-monthly dosing scheme, but monthly schedule may be included as well.
You may also be interested in...
Regeneron Plays It Safe With Eylea, Aims To Undercut Lucentis
Regeneron has designed the launch strategy of its bimonthly wet AMD injection Eylea to head off any reimbursement issues.
Regeneron Plays It Safe With Eylea, Aims To Undercut Lucentis
Regeneron has designed the launch strategy of its bimonthly wet AMD injection Eylea to head off any reimbursement issues.
Ready To Launch But Nowhere To Go: Regeneron's Eylea Gets FDA Delay
The biotech says it is prepared to launch the wet-AMD drug immediately following FDA approval, which is now expected by Nov. 18.